<DOC>
	<DOCNO>NCT02827890</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic drug interaction sitagliptin lobeglitazone healthy male volunteer .</brief_summary>
	<brief_title>CKD-396 Drug-drug Interaction Study ( B ) ( CKD-396 DDI ( B ) P1 )</brief_title>
	<detailed_description>To healthy male subject twenty ( 20 ) , follow treatment administer dosing period wash-out period minimum 10 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . A healthy male whose age 19 year old visit initial screen test . 2 . Body mass index ( BMI ) 17.5~30.5 kg/m^2 body weight must 55kg ( Body mass index ( BMI ) = weight ( kg ) / height ( ) ^2 ) . 3 . A male congenital chronic disease three year , history symptom internal treatment , knowledge area . 4 . Due special characteristic drug , participators must qualify clinical screening examine hematology test blood chemistry analysis , urinary test , electrocardiogram ( ECG ) , etc . 5 . The participant must volunteer sign inform consent document proven Chonbuk National University IRB join study show give informed purpose test special characteristic drug . 6 . The participant must ability willingness participate throughout entire trial . 1 . A person history symptom clinically aware blood , kidney , internal secretion , gastrointestinal , urinary system , cardiovascular , liver , mental , nercous , allergic ( except subclinical seasonal allergy treat injecion ) desease . 2. Who gistory gastrointestinal related disease affect drug absorption ( esophageal achalasia , esophagostenosis , esophageal disease , Crohn 's disease ) surgery ( except simple appendectomy herniotomy ) . 3. Who follow result examination ( a. ALT AST &gt; twice high normal value ) . 4. Who constantly intake 210 g/week alcohol within 6 month screen . ( cup beer ( 5 % ) ( 250 mL ) = 10 g , shot soju ( 20 % ) ( 50mL ) = 8 g , glass wine ( ! 2 % ) ( 125 mL ) = 12g ) . 5. Who participate clinical test take test bioequivalence drug 3 month first clinical drug trial . 6 . Whose blood pressure ≤ 100 ≥150 ( systolic blood pressure ) &lt; 60 ≥ 100 ( diastolic blood pressure ) . 7. Who medical history alcohol drug abuse . 8. Who take drug control metabolic rate ( activatioh inhibithion ) 30 day first take clinical test durg . 9. WHo smoke 20 eigarettes per day . 10. Who take prescribe drug overtheconuter durgs 10 day take first clinical test drug . 11. Who participate whole blood donation 2 month first take clinical test drug platelet donation 1 month first take clinical test drug . 12. Who potent increase danger participate clinical trial sho interrupt interpretin test result serious chronic medical mental status issue result screen examination . 13. Who histroy extreme sensitivity drug contain ingredient Sitagliptin thiazolidinediones drug drug contain Rosiglitazone dug similar effect Rosiglitazone ( Pioglitazone ) . 14. Who serious heart failure congestive heart failure must drugtreated . 15 . A patient hepatopathy . 16 . A patient wevere nephropathy . 17. Who diabetic ketoacidosis diaetic coma , type 1 diabetes , history acute metablic acidosis ketoacidosis . 18 . A patient serious infectious disease severe injury surgery . 19. Who Galactose intolerance , LAPP lactose intolerance , glucosegalactose malabsorption genetic disorder . 20 . Test subject willing unable comply guideline describe protocol . 21 . A person determine unsuitable participate test researcher .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>